首页> 外文期刊>Cell death and differentiation >CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
【24h】

CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma

机译:CD95通过Sck促进胰腺导管腺癌的转移扩散

获取原文
获取原文并翻译 | 示例
       

摘要

Cancer stem cells (CSCs) have been implicated in the initiation and maintenance of tumour growth as well as metastasis. Recent reports link stemness to epithelial-mesenchymal transition (EMT) in cancer. However, there is still little knowledge about the molecular markers of those events. In silico analysis of RNA profiles of 36 pancreatic ductal adenocarcinomas (PDAC) reveals an association of the expression of CD95 with EMT and stemness that was validated in CSCs isolated from PDAC surgical specimens. CD95 expression was also higher in metastatic pancreatic cells than in primary PDAC. Pharmacological inhibition of CD95 activity reduced PDAC growth and metastasis in CSC-derived xenografts and in a murine syngeneic model. On the mechanistic level, Sck was identified as a novel molecule indispensable for CD95's induction of cell cycle progression. This study uncovers CD95 as a marker of EMT and stemness in PDAC. It also addresses the molecular mechanism by which CD95 drives tumour growth and opens tantalizing therapeutic possibilities in PDAC.
机译:癌症干细胞(CSC)与肿瘤生长以及转移的开始和维持有关。最近的报道将干性与癌症中的上皮-间质转化(EMT)联系起来。但是,对于这些事件的分子标记仍然知之甚少。在计算机分析36例胰腺导管腺癌(PDAC)的RNA中,揭示了CD95的表达与EMT和干性之间的关联,该关联已在从PDAC手术标本中分离的CSC中得到验证。转移性胰腺细胞中的CD95表达也高于原发性PDAC。在CSC衍生的异种移植物中和小鼠同基因模型中,CD95活性的药理抑制作用降低了PDAC的生长和转移。在机制水平上,Sck被鉴定为CD95诱导细胞周期进程不可缺少的新型分子。这项研究发现CD95是PDAC中EMT和茎干的标志。它还探讨了CD95驱动肿瘤生长并为PDAC带来诱人的治疗可能性的分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号